CN116509918A - Application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver disease - Google Patents
Application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver disease Download PDFInfo
- Publication number
- CN116509918A CN116509918A CN202310534990.6A CN202310534990A CN116509918A CN 116509918 A CN116509918 A CN 116509918A CN 202310534990 A CN202310534990 A CN 202310534990A CN 116509918 A CN116509918 A CN 116509918A
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- alcoholic fatty
- liver disease
- group
- mix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229930014626 natural product Natural products 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title description 5
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims abstract description 57
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims abstract description 53
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 53
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims abstract description 45
- 235000017060 Arachis glabrata Nutrition 0.000 claims abstract description 24
- 235000010777 Arachis hypogaea Nutrition 0.000 claims abstract description 24
- 235000018262 Arachis monticola Nutrition 0.000 claims abstract description 24
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 claims abstract description 24
- 210000004185 liver Anatomy 0.000 claims abstract description 24
- 235000020232 peanut Nutrition 0.000 claims abstract description 24
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 claims abstract description 16
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 241001553178 Arachis glabrata Species 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims description 76
- 230000036541 health Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 230000000968 intestinal effect Effects 0.000 abstract description 12
- 230000000813 microbial effect Effects 0.000 abstract description 4
- 238000011713 fatty liver animal model Methods 0.000 abstract 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 35
- 235000009200 high fat diet Nutrition 0.000 description 31
- 244000105624 Arachis hypogaea Species 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000004480 active ingredient Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 9
- 229960005420 etoposide Drugs 0.000 description 9
- 230000003362 replicative effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000005936 beta-Galactosidase Human genes 0.000 description 8
- 108010005774 beta-Galactosidase Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 229930003935 flavonoid Natural products 0.000 description 7
- 150000002215 flavonoids Chemical class 0.000 description 7
- 235000017173 flavonoids Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- -1 etc. Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 244000005709 gut microbiome Species 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000185686 Apocynum venetum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000013232 NAFLD rodent model Methods 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229930182491 iridoid glucoside Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides application of three natural product combinations in preparing a medicine for treating non-alcoholic fatty liver, wherein the medicine is prepared from three natural products of peanut skin active components, geniposide and isoquercitrin according to a mass ratio of 16:10:1. According to the invention, through a non-alcoholic fatty liver disease animal model, the effects of reducing the weight and the liver fat content of the peanut coat active component, geniposide and isoquercitrin which are combined can be regulated by the microbial intestinal flora and TLR4-NF kB and AMPK signal paths are proved, and the non-alcoholic fatty liver disease animal model has obvious improvement effect on clinical symptoms of the non-alcoholic fatty liver disease. Can be applied to preparing medicines for treating non-alcoholic fatty liver disease, and also can be applied to preparing foods for preventing and treating non-alcoholic fatty liver disease and health foods.
Description
Technical Field
The invention belongs to the field of medical foods of compounds, and relates to application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver, in particular to application of peanut coat active components, geniposide and isoquercetin combinations in preparation of medicines for treating non-alcoholic fatty liver.
Background
Nonalcoholic fatty liver disease refers to a clinical pathological syndrome characterized mainly by excessive deposition of intracellular fat in liver cells, except for alcohol and other definite liver-damaging factors, and is an acquired metabolic stress liver injury closely related to insulin resistance and genetic susceptibility. Including simple fatty liver, nonalcoholic steatohepatitis and liver cirrhosis related to the same, and serious liver cancer can also be caused.
Non-alcoholic fatty liver disease has progressed from a relatively unknown disease to the most common cause of chronic liver disease worldwide over the last 20 years. It is reported that 25% of the population worldwide is currently considered to suffer from non-alcoholic fatty liver disease, and recent studies predict that the incidence of non-alcoholic fatty liver disease will also be increasing, which will lead to a tremendous clinical and economic burden. Therefore, the development of drugs for non-alcoholic fatty liver disease is being advanced.
At present, steady progress is made in elucidating pathogenesis of non-alcoholic fatty liver disease, determining therapeutic targets and promoting drug development, but no drugs for treating the disease are available in the market. As a multifactorial disease, nonalcoholic fatty liver disease involves a complex series of metabolic changes, and many monotherapy effects against nonalcoholic fatty liver disease are clinically undesirable, with no more than 40% of patients benefiting from monotherapy. The natural products often act on multiple targets and have small toxic and side effects, and the combination of multiple natural products has the advantages of improving the curative effect, reducing the side effects and the like. Therefore, the treatment of nonalcoholic fatty liver disease has been increasingly developed after the combination of various natural products.
Peanut skin active ingredient (PSE), geniposide (PC) and Isoquercitrin (IQC) are three pharmaceutically and dietetically homologous active ingredients with anti-aging activity and a single compound. The active component of peanut coat is mainly composed of oligosaccharide and flavonoid, geniposide is an iridoid glucoside, which is the main medicinal component of fructus Gardeniae, and isoquercetin is flavonoid derived from herba Apocyni Veneti. We found that the mixture of peanut coat active ingredient, geniposide and isoquercitrin prepared in a mass ratio of 16:10:1 produced significant prophylactic effects on experimental non-alcoholic fatty liver disease mice by modulating the intestinal flora, AMPK and TLR4-NF kB signaling pathways.
Disclosure of Invention
The invention aims to provide application of three natural product combinations in preparing medicaments for treating non-alcoholic fatty liver diseases, which are prepared by combining active components (PSE) of peanut skin with anti-aging activity, flavonoid compound geniposide (PC) and flavonoid compound Isoquercetin (IQC), wherein the mass ratio of the components is PSE to the PC to the IQC=16 to 10 to 1. The preparation method of peanut coat active component has been published in patent (patent No. ZL 2019 1 0040231.8), mainly comprises oligosaccharide and flavonoid substances, and has geniposide (PC) structure shown in fig. 1 and Isoquercitrin (IQC) structure shown in fig. 2.
It is another object of the present invention to provide the use of the three natural product combinations in health products or foods for weight reduction and liver fat reduction. The three natural products are peanut skin active components (PSE), flavonoid geniposide (PC) and flavonoid Isoquercetin (IQC), and the mass ratio of the components is PSE to PC to IQC=16 to 10 to 1.
The peanut coat active ingredient, geniposide, and isoquercetin may be prepared in accordance with any conventional procedure in a pharmaceutically acceptable carrier or diluent. The pharmaceutically acceptable carrier as described herein refers to a pharmaceutical carrier conventional in the pharmaceutical field, such as diluents, excipients, etc., fillers such as starch, sucrose, microcrystalline cellulose, etc.; binders such as starch slurry, hydroxypropylcellulose, gelatin, polyethylene glycol, etc.; wetting agents such as magnesium stearate, silica gel micropowder, polyethylene glycols, etc.; absorption promoter such as polysorbate, lecithin, etc., surfactant such as poloxamer, sorbitan fatty acid, polysorbate, etc., and other adjuvants such as flavoring agent, sweetener, etc. can be added into the composition.
The dosage forms for administration may be tablets, pills, powders, dispersible tablets, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft capsules, hard capsules, sterile injectable solutions, liniments or suppositories. Can be made into conventional quick release, slow release or delayed release.
The mixture of the present invention may be administered by a variety of routes including oral, intramuscular, subcutaneous, intraperitoneal, intravenous injection, and the like.
The invention has the advantages that the raw materials adopted by the invention are peanut, gardenia and apocynum venetum which are easy to obtain and rich in resources. Peanut coats are used in traditional Chinese medicine for treating hemophilia, primary and secondary thrombocytopenic purpura, liver hemorrhage, etc. Fructus Gardeniae is used for treating icteric hepatitis, sprain and contusion, hypertension, diabetes, etc. in clinical practice. Herba Apocyni Veneti has effects of clearing heat, lowering blood pressure, tonifying heart, promoting urination, and treating heart disease. The three components are prepared into a medicine according to the mass ratio of 16:10:1, and the medicine has remarkable prevention effect on the high-fat-induced non-alcoholic fatty liver disease mice. And has no obvious toxic and side effects.
In the anti-aging activity assay, the above active ingredients and single compounds and mixtures thereof all extended the replicative life of K6001 yeast (FIG. 3).
In the anti-aging activity assay, the above active ingredients and single compounds and mixtures thereof all inhibited etoposide-induced PC12 cell senescence (FIGS. 4-5).
In the in vivo experiments for preventing the non-alcoholic fatty liver disease, the mixture can be found to remarkably reduce the food intake, the weight and the intestinal microbial flora change of a non-alcoholic fatty liver disease model mouse and reduce fat infiltration in the liver compared with a single component or a single compound (figures 6-11). The above mixture can produce the effect of preventing nonalcoholic fatty liver disease by modulating intestinal microbiota and AMPK and TLR4-NF kB signaling pathways (FIGS. 9-13).
Drawings
Fig. 1 is a view of geniposide (PC) structure.
FIG. 2 is a diagram of the structure of Isoquercetin (IQC).
FIG. 3 is the effect of peanut coat active ingredient (PSE), geniposide (PC), isoquercetin (IQC), and mixtures thereof (MIX) on replicative longevity of K6001 yeasts. In the figure: * P <0.05, < P <0.01, < P <0.001 represents the treatment group vs blank group.
FIG. 4 is the effect of PSE, PC, IQC and mixtures thereof (MIX) on etoposide-induced aging PC12 cells. In the figure, the numbers in brackets indicate the proportion of cells stained blue in the field of view (i.e., cells containing the cellular senescence β -galactosidase marker) to all cells.
FIG. 5 is a graph quantifying the effect of PSE, PC, IQC and mixtures thereof (MIX) on etoposide-induced senescent PC12 cells. In the figure, P<0.05,**P<0.01,***P<0.001 represents a model control vs blank, # P<0.05, ## P<0.01, ### P<0.001 represents the treatment group vs model control group.
FIG. 6 is a graph of the effect of MET, PSE, PC, IQC and MIX (MIX) on body weight, food intake and water intake of non-alcoholic fatty liver disease mice. In the figure: * P (P)<0.05,**P<0.01,***P<0.001 represents the administration group vs high fat diet group, # P<0.05, ## P<0.01, ### P<0.001 represents a high fat diet group vs normal diet group. Number of animals per group: n=10. ND is normal feed group, HFD is high fat feed group, MET is high fat feed group plus metformin group (positive control), PSE is high fat feed group plus peanut coat active group, PC is high fat feed group plus geniposide group, IQC is high fat feed group plus isoquercitrin group, MIX is high fat feed group plus mixture group (PSE+PC+IQC).
FIG. 7 is the result of hematoxylin & eosin staining of liver of non-alcoholic fatty liver disease mice with MET, PSE, PC, IQC and MIX (MIX).
FIG. 8 is a graph showing the results of oil red O staining of liver of non-alcoholic fatty liver disease mice by MET, PSE, PC, IQC and MIX (MIX).
FIG. 9 is the effect of MET, PSE and Mixture (MIX) on the diversity of intestinal flora α in non-alcoholic fatty liver disease mice.
FIG. 10 is the effect of MET, PSE and Mixture (MIX) on β diversity in intestinal flora of non-alcoholic fatty liver disease mice.
FIG. 11 is the effect of MET, PSE and Mixture (MIX) on the composition of non-alcoholic fatty liver disease mice intestinal flora at the portal level.
FIG. 12 is the effect of MET, PSE and Mixture (MIX) on the composition of the intestinal flora of non-alcoholic fatty liver mice at the genus level.
FIG. 13 is the effect of MET, PSE, PC, IQC and Mixture (MIX) on inflammatory factor levels in non-alcoholic fatty liver disease mice. In the figure: * P (P)<0.05,**P<0.01,***P<0.001 represents the administration group vs high fat diet group, # P<0.05, ## P<0.01, ### P<0.001 represents a high fat diet group vs normal diet group.
FIG. 14 is the effect of MET, PSE, PC, IQC and Mixture (MIX) on the levels of AMPK and TLR4-NF kB signaling pathway proteins in non-alcoholic fatty liver disease mice.
Detailed Description
The invention is further described with reference to the drawings and examples.
Example 1 peanut coat active ingredient extraction and ingredient analysis (see patent ZL 2019 1 0040231.8 for details)
The experimental method comprises the following steps:
extracting peanut skin with 60% ethanol for 2 times, 1 hr for the first time and 0.5 hr for the second time, vacuum filtering, concentrating to 1/50 of the original volume, separating with macroporous adsorbent resin HP-20, eluting with 40% ethanol, and collecting the fraction as active component of peanut skin. The peanut coat active component is separated into two parts by High Performance Liquid Chromatography (HPLC) with the following conditions: development ODS-UG-5 (. Phi.20X1250 mm), nomura Chemical column, flow rate of 6ml/min, isocratic elution with 18% methanol, and collection as saccharide component; 15-25min, 18-100% methanol gradient elution, 25-40min,100% methanol isocratic elution, and collecting as non-saccharide component. The saccharide and non-saccharide fraction fractions were then analyzed by spectroscopic analysis, high resolution mass spectrometry and chemical derivatization methods.
Experimental results:
analysis of these two fractions confirmed that the two fractions were a saccharide fraction and a non-saccharide fraction, respectively. The saccharide part mainly comprises arabinose, xylose, D- (+) -inositol, myo-inositol, mannose, glucose and galactose, and the molar ratio is 3:6.9:1:1.5:3.2:21.5:3.8. The non-sugar moiety consists of polyphenols, mainly including dimers, trimers and tetramers of procyanidins of type a or type B (table 1).
TABLE 1 Main chemical Components of peanut coat active ingredients
Example 2 Effect of peanut coat active ingredient (PSE), geniposide (PC), isoquercetin (IQC), and mixtures thereof (MIX) on replicative longevity of K6001 Yeast
The experimental method comprises the following steps:
the effect of PSE, PC, IQC alone or after mixing on replicative life of K6001 yeasts was determined using the K6001 yeast system (a system for evaluating anti-aging activity of compounds). K6001 yeast cells frozen at-30℃were first inoculated into 5 ml of galactose liquid medium (containing 3% galactose, 2% polypeptone and 1% yeast extract) and cultured with shaking at 28℃for 24 hours. The next day 5 ml of glucose solid medium (containing 2% glucose, 2% polypeptone, 2% agar and 1% yeast extract) was poured into small glass dishes, and 150 μl of absolute ethanol or different concentrations of sample solution were added to each dish after the medium solidified. After the solvent had evaporated, 1 ml of yeast cells incubated for 24 hours were taken in a centrifuge tube and washed three times with 9 ml of PBS. The washed yeast cells were counted by a blood cell counting plate, and about 4000 yeast cells were uniformly spread in a small dish and subjected to stationary culture at 28℃for 48 hours. Each dish was randomly picked under a microscope for 40 microcolonies and the number of subcellular (i.e., algebraic) of each microcolonie was calculated. The experiment uses resveratrol with the concentration of 2.282 mug/mL as a positive control.
Experimental results:
PSE significantly extended K6001 yeast replicative life at 3 and 10 μg/mL (FIG. 3A), PC significantly extended K6001 yeast replicative life at 3.884 μg/mL (FIG. 3B), IQC significantly extended K6001 yeast replicative life at 1.393 and 4.644 μg/mL (FIG. 3C), and mixtures thereof significantly extended K6001 yeast replicative life at 1 μg/mL PSE+0.0625 μg/mL PC+0.0625 μg/mL and 3 μg/mL PSE+1.875 μg/mL PC+0.1875 μg/mL IQC concentrations with average algebraic higher than these three components acting alone (FIG. 3A-FIG. 3D). The above results demonstrate that a better prolongation of the replicative life of K6001 yeast can be achieved by combining PSE, PC and IQC.
Example 3 Effect of PSE, PC, IQC and mixtures thereof (MIX) on Etoposide-induced aging PC12 cells
The experimental method comprises the following steps:
PC12 cells were inoculated into a 24-well plate containing CM culture solution, after culturing in a carbon dioxide incubator at 37℃for 1 day, CM culture solution was changed to EM culture solution containing no-use sample concentration, after culturing in an incubator at 37℃for another 1 day, culture solution was changed to EM culture solution containing etoposide at 1 micromolar concentration, and culturing was continued for another 1 day (the blank control group was replaced with EM culture solution containing no etoposide). After washing with PBS, 200. Mu.l of 4% paraformaldehyde was added, and after fixation for 15 minutes at room temperature, the cell fixative was aspirated, after washing 3 times with PBS, 200. Mu.l of staining working fluid (containing 10. Mu.l of beta-galactosidase staining fluid A, 10. Mu.l of beta-galactosidase staining fluid B, 930. Mu.l of beta-galactosidase staining fluid C and 50. Mu.l of X-Gal solution) was added, and the mixture was sealed with a preservative film to avoid evaporation of the solution and incubated overnight in a 37℃incubator without carbon dioxide. Cells were observed under a normal light microscope and the proportion of cells stained blue in the field of view (i.e., cells containing the cell senescence β -galactosidase marker) to all cells was calculated. The experiment uses rapamycin at a concentration of 0.457 μg/mL as a positive control.
Experimental results:
the negative control group had 14.95% of cells that were positive for age-related beta-galactosidase, while etoposide induced aging of PC12 cells, making 35.76% of cells positive for age-related beta-galactosidase (fig. 4). Etoposide-induced PC12 cells exhibited various degrees of reduction in senescence-associated beta-galactosidase positives following addition of various concentrations of PSE, PC, IQC and mixtures thereof, with 0.1, 0.3, 1, 3, 10. Mu.g/mL PSE,0.388, 1.165, 3.884. Mu.g/mL PC,0.464, 1.393, 4.644. Mu.g/mL IQC and mixtures thereof (mixed at 16:10:1) being most effective (FIGS. 4-5). These results indicate that combining PSE, PC and IQC inhibits etoposide-induced aging of PC12 cells.
Example 4 influence of mixture of PSE, PC, IQC (MIX) on weight, food intake and Water intake of non-alcoholic fatty liver disease mice
The experimental method comprises the following steps:
in this example, six week old male mice were divided into seven groups of ten mice. The normal feed group (ND) was drenched with water and normal diet. The High Fat Diet (HFD) control group was infused with the same amount of vehicle and fed the high fat diet ad libitum. The high fat diet plus metformin group (MET, positive control) was infused with metformin at a dose of 140 mg/kg body weight/day and fed ad libitum with high fat diet and drinking water. The high-fat feed and peanut coat active ingredient group (PSE) are infused with the peanut coat active ingredient according to the dosage of 80 mg/kg body weight/day and the high-fat feed and drinking water are freely taken. The high-fat feed plus geniposide group (PC) is infused with geniposide according to the dosage of 50 mg/kg body weight/day and can freely eat the high-fat feed and drink water. The high-fat feed plus isoquercitrin group (IQC) is infused with isoquercitrin at a dosage of 5 mg/kg body weight/day and fed with high-fat feed and drinking water freely. The high-fat diet plus MIX group (MIX, PC, IQC 80, 50, 5 mg/kg body weight/day) was infused with the MIX and was free to ingest the high-fat diet and drinking water. The experimental period was 12 weeks, and body weight, food intake, and water intake were recorded weekly.
Experimental results:
the mice in the HFD group had a significantly increased body weight and feed intake compared to the mice in the ND group (FIG. 6). The MET and PSE mice had significantly less body weight, no significant change in PC and IQC group body weight, and the MIX group body weight was most reduced compared to the HFD group (fig. 6A). The HFD group had significantly increased food intake and each treatment group had decreased food intake relative to the HFD group (FIG. 6B). However, the water intake of the HFD group was reduced relative to the ND group, as was the water intake of each treatment group (FIG. 6C). Thus, the MIX group had a remarkable weight-reducing effect.
EXAMPLE 5 Effect of mixture of PSE, PC, IQC (MIX) on non-alcoholic fatty liver disease mouse tissue and serum Triglycerides, total cholesterol and liver function index
The experimental method comprises the following steps:
after the last administration, the animals are fasted without water forbidding for 12 hours, blood is taken to detect indexes of TG (triglyceride), TC (total cholesterol), AST (aspartate aminotransferase) and ALT (alanine aminotransferase) in serum, and tissues such as liver, fat, spleen, kidney and the like are taken for weighing.
Experimental results:
comparing the tissue weights of the groups (table 2), it was found that the fat of MET, PSE and MIX groups was significantly reduced relative to the HFD group, the liver weights of the administered groups and HFD groups were significantly different, and the MIX group liver weight was most reduced. Therefore, MIX has a remarkable effect of reducing the weight of fat and liver tissue.
TABLE 2 influence of mixture of PSE, PC, IQC (MIX) on tissue weight of non-alcoholic fatty liver disease mice
In addition, the serum indices were compared (Table 3), and it was found that there was a significant difference between the serum indices of each administration group and the HFD group, indicating that MIX improved liver function index in mice.
TABLE 3 influence of mixture of PSE, PC, IQC (MIX) on serum index of non-alcoholic fatty liver disease mice
Group of | ALT(U/L) | AST(U/L) | TG(mmol/L) | TC(mmol/L) |
ND | 34.67±4.96 | 87.74±6.79 | 1.58±0.18 | 2.96±0.30 |
HFD | 51.85±7.89 ## | 142.33±26.34 ### | 1.96±0.21 ## | 4.16±0.37 ### |
MET | 24.14±3.79 *** | 96.23±14.56 ** | 1.11±0.17 *** | 3.50±0.35 * |
PSE | 26.91±5.80 *** | 95.69±16.07 ** | 1.03±0.11 *** | 3.68±0.37 |
PC | 24.27±4.15 *** | 92.34±13.08 ** | 0.81±0.14 *** | 3.44±0.18 ** |
IQC | 28.04±2.32 *** | 87.49±10.77 *** | 0.83±0.12 *** | 3.64±0.37 |
MIX | 25.6±3.95 *** | 86.82±12.66 ** | 0.82±0.12 *** | 3.73±0.14 * |
In this test, ALT stands for alanine aminotransferase, AST stands for aspartate aminotransferase, TG for triacylglycerol, and TC for total cholesterol; #,##,### shows that the high-fat feed group is compared with the normal feed group P<0.05,P<0.01,P<0.001; *,**,*** The expression of P in the administration group compared with the high-fat diet group<0.05,P<0.01,P<0.001; the number of animal samples was 8.
Example 6 Effect of mixture of PSE, PC, IQC (MIX) on liver pathology in non-alcoholic fatty liver disease mice
The experimental method comprises the following steps:
the livers of mice were taken and fixed in 4% paraformaldehyde solution for 48 hours, a portion of the livers after fixation was embedded with paraffin to prepare paraffin sections (section thickness 3 μm), another portion was embedded with OCT after gradient dehydration with 15% and 30% sucrose solution to prepare frozen sections (section thickness 10 μm), the paraffin sections were subjected to hematoxylin & eosin staining, and the frozen sections were subjected to oil red O staining.
Experimental results:
hematoxylin & eosin staining results showed that HFD group had severe hepatocyte damage, and administration group was able to reduce hepatocyte damage in mice, with MIX group having the best effect of reducing hepatocyte damage (fig. 7). Oil red O staining showed severe liver fat accumulation in HFD groups, with the MIX group reducing liver fat content the most (fig. 8). The results show that the mixture MIX of PSE, PC, IQC can reduce liver fat content in non-alcoholic fatty liver disease mice and alleviate liver cell damage in non-alcoholic fatty liver disease mice.
Example 7 effect of pse, pc, iqc Mixture (MIX) on intestinal microbiota of non-alcoholic fatty liver disease mice.
The experimental method comprises the following steps:
after 12 weeks of dosing, the cages were cleaned and alcohol sterilized and samples of approximately 100 mg (2-3 grains) of the faeces of the mice from group ND, HFD, MET, PSE and MIX were collected. DNA was extracted and the 16S rDNA V4 region of the sample was amplified according to the designated sequencing region. And PE250 sequencing analysis was performed using a Hiseq 2500 instrument. The experimental results were analyzed for intra-group species diversity and inter-group species differences.
Experimental results:
the results of the analysis of the α diversity of the intestinal microbiota of mice (fig. 9) showed that the HFD group significantly reduced the species richness of the intestinal microbiota of mice, while each dosing group restored it to the same level as the ND group. Beta diversity analysis (fig. 10) showed that HFD group significantly changed the mice intestinal flora composition, whereas each dosing group had an intestinal flora composition close to ND group, with MIX group intestinal flora composition closest to ND group. The species analysis results showed that at the portal level, the abundance of MIX group Bacteroidota (bacteroides) increased (fig. 11). This is mainly because at the genus level, MIX group significantly increases the abundance of lactobacillus salivarius (fig. 12), a beneficial bacterium having antibacterial, immune and intestinal microbial action, and studies have demonstrated that lactobacillus salivarius can improve nonalcoholic fatty liver disease.
The results show that the mixture MIX of PSE, PC and IQC can regulate the intestinal microbial environment homeostasis of non-alcoholic fatty liver disease mice.
Example 8 effect of pse, pc, iqc Mixture (MIX) on inflammatory factor levels in non-alcoholic fatty liver disease mice.
The experimental method comprises the following steps:
mouse liver 30-50 mg collected after dissection was taken, 500. Mu.l PBS and 5. Mu.l protease inhibitor were added, the tissues were ground, and supernatant was collected after centrifugation at 12000rpm and 4℃to obtain a mouse liver protein solution, and mouse liver and serum LPS (lipopolysaccharide), TNF-. Alpha. (tumor necrosis factor) and IL-6 (interleukin-6) levels were measured using an Elisa kit. In addition, 30-50 mg of the feces of the mice collected at 12 weeks of administration were taken, milled with PBS, centrifuged, the supernatant was taken, filtered with a 0.22 μm filter membrane, and inactivated in a water bath at 90℃for 15 minutes, and the LPS level was measured with an Elisa kit.
Experimental results:
inflammatory factor level measurements are shown in figure 13. The HFD group significantly increased the levels of mouse fecal LPS and serum and liver LPS, TNF- α and IL-6, while the levels of these inflammatory factors were significantly reduced in each of the dosing groups (FIGS. 13A-G). The results indicate that MIX is able to reduce the inflammatory level in mice.
Example 8 effect of PSE, PC, IQC Mixture (MIX) on protein expression levels in non-alcoholic fatty liver disease mice.
The experimental method comprises the following steps:
the method comprises the steps of taking 30-50 mg of mouse liver collected after dissection of the mouse, adding 500 microliter of RIPA lysate, 5 microliter of protease inhibitor and phosphorylation inhibitor, grinding tissues, centrifuging, collecting supernatant to obtain a mouse liver protein solution, and taking the same amount of protein solution from each group for immunoblotting after measuring protein concentration so as to measure the expression level of the mouse liver protein.
Experimental results:
the results of protein expression level measurement are shown in FIG. 14. The HFD group significantly increased the expression levels of inflammation-associated proteins such as mouse liver TLR4 (Toll-like receptor 4), phosphorylated IKKK beta (activating factor-stimulated enzyme inhibitor beta), phosphorylated IKB alpha (nuclear factor kappa B-inhibited protein alpha), etc., while the expression levels of these proteins were significantly decreased in each of the administration groups (FIG. 14A). While protein expression levels associated with fatty acid synthesis and metabolism were reduced in HFD groups, phosphorylated AMPK (adenylate activated protein kinase) and phosphorylated ACC (acetyl CoA carboxylase), etc., these protein expression levels were significantly increased in each of the administration groups (FIG. 14B). The result shows that MIX can regulate TLR4-NF kB and AMPK signal paths, thereby achieving the effect of preventing nonalcoholic fatty liver diseases.
In this test, 1,2 is ND, 3,4 is HFD, 5,6 is MET, 7,8 is PSE, 9,10 is PC, 11,12 is IQC, and 13,14 is MIX.
Claims (4)
1. The application of the combination of three natural products in preparing the medicine for treating the non-alcoholic fatty liver disease is characterized in that the three natural products are peanut skin active components, geniposide and isoquercitrin, and the combination mass ratio is 16:10:1.
2. The use according to claim 1, wherein the medicament is in the form of a solid or liquid formulation and the route of administration is enteral or parenteral.
3. The application of the combination of three natural products in preparing health care products or foods for reducing weight and liver fat content is characterized in that the three natural products are peanut skin active components, geniposide and isoquercitrin, and the combination mass ratio is 16:10:1.
4. The use according to claim 3, wherein the formulation of the health product or food is a solid or liquid formulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310534990.6A CN116509918A (en) | 2023-05-12 | 2023-05-12 | Application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310534990.6A CN116509918A (en) | 2023-05-12 | 2023-05-12 | Application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116509918A true CN116509918A (en) | 2023-08-01 |
Family
ID=87397467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310534990.6A Pending CN116509918A (en) | 2023-05-12 | 2023-05-12 | Application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver disease |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116509918A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109620857A (en) * | 2019-01-16 | 2019-04-16 | 浙江大学 | Peanut coat active component and its preparing the application in anti-fat antidiabetic medicine |
CN113750109A (en) * | 2021-09-08 | 2021-12-07 | 山东睿鹰制药集团有限公司 | Application of isoquercetin in treatment of steatohepatitis |
-
2023
- 2023-05-12 CN CN202310534990.6A patent/CN116509918A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109620857A (en) * | 2019-01-16 | 2019-04-16 | 浙江大学 | Peanut coat active component and its preparing the application in anti-fat antidiabetic medicine |
CN113750109A (en) * | 2021-09-08 | 2021-12-07 | 山东睿鹰制药集团有限公司 | Application of isoquercetin in treatment of steatohepatitis |
Non-Patent Citations (2)
Title |
---|
刘倩,等: "京尼平苷治疗非酒精性脂肪性肝病的潜在生物学效应", 中西医结合肝病杂志, vol. 29, no. 3, 31 March 2019 (2019-03-31), pages 285 - 288 * |
房仙颖,等: "异槲皮素的制备及研究进展", 天然产物研究与开发, vol. 32, 31 December 2020 (2020-12-31), pages 708 - 717 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11986553B2 (en) | Multi-component injection | |
US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
EP2077851B1 (en) | A pharmaceutical composition comprising cordycepin for the treatment and prevention of obesity | |
KR101817552B1 (en) | Composition for preventing or treating hepatitis comprising monoacetyl-diacylglycerol compound | |
KR101446179B1 (en) | A composition for Inflammatory Disorder comprising the polyphenol extracts from Phellinus baumii | |
US9757408B2 (en) | Therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient | |
Lou et al. | Linderae radix ethanol extract attenuates alcoholic liver injury via attenuating inflammation and regulating gut microbiota in rats | |
Fan et al. | Fermented ginseng attenuates lipopolysaccharide-induced inflammatory responses by activating the TLR4/MAPK signaling pathway and remediating gut barrier | |
CN107441078A (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
Meng et al. | Polysaccharides from extracts of Antrodia camphorata mycelia and fruiting bodies modulate inflammatory mediator expression in mice with polymicrobial sepsis | |
US9303006B2 (en) | Line leaf inula flower lactone A and methods for preparing and using the same for treating myocarditis | |
JP5622222B2 (en) | Hypolipidemic composition and use thereof | |
Yi et al. | Intervention effects of lotus leaf flavonoids on gastric mucosal lesions in mice infected with Helicobacter pylori | |
CN104688933B (en) | Composition of Pu' er tea effective components and application thereof in preparing hypoglycemic drug or health food | |
CN116509918A (en) | Application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver disease | |
CN102153630B (en) | Ring octapeptide and preparation method and application thereof in medicament making | |
CN109620857B (en) | Peanut coat active component and application thereof in preparation of anti-obesity and anti-diabetic drugs | |
US20210002707A1 (en) | Nanovesicles derived from blautia bacteria and use thereof | |
KR102658362B1 (en) | A Composition for Preventing or Treating Metabolic Disorders Comprising Benzylaminoethanol Devatives as Active Ingredients | |
CN114159499B (en) | Traditional Chinese medicine composition for treating hepatic fibrosis and preparation method and application thereof | |
KR102623896B1 (en) | Composition for reducing body weight, body fat, or blood sugar including neohesperidin dihydrochalcone glycotransferase | |
CN103288889A (en) | Anthraquinone derivatives, their pharmaceutical compositions and application in medicine preparation | |
Lin et al. | Fermented Astragalus Membranaceus by Bacillus subtilis Ameliorates Hyperuricemia in Mice by Suppressing Inflammation via Reducing p38 MAPK and NF-κB Phosphorylation | |
US8012486B2 (en) | Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient | |
CN114767705A (en) | Application of polygonatum odoratum polysaccharide in preparation of medicine for treating lung injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |